Jasper Net Income Per Share from 2010 to 2024

JSPRW Stock  USD 0.22  0.01  4.76%   
Jasper Therapeutics Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to -6.48 in 2024. During the period from 2010 to 2024, Jasper Therapeutics Net Loss regression line of quarterly data had r-squared of  0.60 and coefficient of variation of (55.28). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
(6.18)
Current Value
(6.48)
Quarterly Volatility
47.82391456
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 11.2 M or Other Operating Expenses of 40 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.1. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Jasper Therapeutics Correlation against competitors.
For more information on how to buy Jasper Stock please use our How to Invest in Jasper Therapeutics guide.

Latest Jasper Therapeutics' Net Income Per Share Growth Pattern

Below is the plot of the Net Income Per Share of Jasper Therapeutics over the last few years. It is Jasper Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jasper Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Income Per Share10 Years Trend
Slightly volatile
   Net Income Per Share   
       Timeline  

Jasper Net Income Per Share Regression Statistics

Arithmetic Mean(86.51)
Coefficient Of Variation(55.28)
Mean Deviation40.76
Median(114.30)
Standard Deviation47.82
Sample Variance2,287
Range108
R-Value0.77
Mean Square Error990.94
R-Squared0.60
Significance0.0007
Slope8.27
Total Sum of Squares32,020

Jasper Net Income Per Share History

2024 -6.48
2023 -6.18
2022 -6.63
2021 -21.05

About Jasper Therapeutics Financial Statements

Jasper Therapeutics investors use historical fundamental indicators, such as Jasper Therapeutics' Net Income Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jasper Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss(6.18)(6.48)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jasper Stock Analysis

When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.